Should You Buy Novo Nordisk After the Huge Investor Update?
Novo Nordisk (NVO 1.89%) is struggling with competition in its weight loss treatment business and is looking to make an acquisition to bolster its pipeline of drugs.
Trump administration reaches deal to lower prices of obesity and diabetes drugs
The Trump administration has announced agreements with pharmaceutical companies Novo Nordisk (NYSE:NVO) and Eli Lilly and Co (NYSE:LLY) to reduce the cost of GLP-1 medications used to treat obesity, diabetes, and related conditions. The initiative seeks to expand access and affordability for millions of Americans, including those covered by Medicare and Medicaid.
Novo Nordisk A/S (NVO) Q3 2025 Earnings Call Transcript
Novo Nordisk A/S (NVO) Q3 2025 Earnings Call November 5, 2025 6:30 AM EST Company Participants Jacob Martin Rode - Head of Investor Relations Maziar Doustdar - President, CEO & Member of the Management Board Ludovic Helfgott - Executive VP of Product & Portfolio Strategy and Member of Management Board David Moore - Executive VP of US Operations & Member of Management Board Martin Lange - EVP of R&D, Chief Scientific Officer and Member of the Management Board Karsten Knudsen - Executive VP, CFO & Member of the Management Board Conference Call Participants Carsten Madsen - Danske Bank A/S, Research Division Peter Verdult - BNP Paribas, Research Division Florent Cespedes - Sanford C. Bernstein & Co., LLC.
Novo Nordisk Q3: Why I'm Not Giving Up Yet
Novo Nordisk A/S shares have plunged nearly 70%, yet the company remains a leader in GLP-1 and obesity drugs with strong growth catalysts. Despite fierce competition and a recent reset phase, NVO's Q3 2025 showed net sales up 15% at CER and operating profit up 21% excluding one-offs. Obesity Care, led by Wegovy, saw 41% sales growth at CER, and the upcoming Wegovy pill approval could significantly boost adoption and revenue.
Novo Nordisk says its head of manufacturing is stepping down
Wegovy maker Novo Nordisk said on Wednesday that its executive vice president in charge of manufacturing was stepping down.
Novo Nordisk accepts Ozempic, Wegovy and Rybelsus prices in US Medicare negotiations
Novo Nordisk said on Wednesday it has accepted the U.S. Inflation Reduction Act (IRA)'s maximum fair price for its diabetes and obesity medicines Ozempic, Wegovy and Rybelsus, which will become effective in January 2027.
Ozempic Maker Novo Nordisk Lowers Growth Outlook of Its Blockbuster Drugs
Intensifying competition, pricing pressure and copycat versions of Ozempic and Wegovy hold back sales at the pharma giant.
Ozempic maker Novo Nordisk lowers growth outlook for its weight loss drugs as pricing pressures mount
A slew of headwinds has shaken investor confidence in what was once Europe's most valuable firm. Novo Nordisk is currently locked in a bidding war with Pfizer for U.S. biotech firm Metsera.
Rollercoaster year for Novo Nordisk: Investors await new earnings report
Novo Nordisk has been on a rollercoaster this year, with stiff competition in the weight-loss drugs space. Ahead of their third quarter earnings, CNBC's Silvia Amaro takes a look at what's at stake for the Danish giant.
Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?
NVO faces slowing Wegovy and Ozempic momentum, pricing risks and fierce competition ahead of Q3 earnings.
Novo Nordisk's Wegovy could soon have a new sales outlet in the U.S.
Telehealth company Hims & Hers says it is in “active discussions” with Novo Nordisk about selling Wegovy.
Novo Nordisk: Governance Shakeup Amid Broader Headwinds
Novo Nordisk continues to underperform the S&P 500, with a 42.5% YTD decline versus the index's 16.3% gain. NVO's struggles are not solely due to sector weakness, as the Healthcare sector (XLV) is up nearly 5% YTD. Recent sharp EPS downgrades for both Q3 and Q4 2025 highlight fundamental issues, likely margin compression and cost control challenges.
